Radiation Oncology Journal

The Korean Society for Radiation Oncology (대한방사선종양학회)
권호 표지
DOI QR코드

DOI QR Code

FXYD-3 expression in relation to local recurrence of rectal cancer

  • Loftas, Per (Division of Surgery, Department of Clinical and Experimental Medicine, Linkoping University) ;
  • Arbman, Gunnar (Division of Surgery, Department of Clinical and Experimental Medicine, Linkoping University) ;
  • Sun, Xiao-Feng (Division of Oncology, Department of Clinical and Experimental Medicine, Linkoping University) ;
  • Edler, David (Department of Surgery, Karolinska Institute) ;
  • Syk, Erik (Department of Surgery, Ersta Hospital) ;
  • Hallbook, Olof (Division of Surgery, Department of Clinical and Experimental Medicine, Linkoping University)
  • Received : 2015.11.18
  • Accepted : 2016.03.14
  • Published : 2016.03.31
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: In a previous study, the transmembrane protein FXYD-3 was suggested as a biomarker for a lower survival rate and reduced radiosensitivity in rectal cancer patients receiving preoperative radiotherapy. The purpose of preoperative irradiation in rectal cancer is to reduce local recurrence. The aim of this study was to investigate the potential role of FXYD-3 as a biomarker for increased risk for local recurrence of rectal cancer. Materials and Methods: FXYD-3 expression was immunohistochemically examined in surgical specimens from a cohort of patients with rectal cancer who developed local recurrence (n = 48). The cohort was compared to a matched control group without recurrence (n = 81). Results: Weak FXYD-3 expression was found in 106/129 (82%) of the rectal tumors and strong expression in 23/129 (18%). There was no difference in the expression of FXYD-3 between the patients with local recurrence and the control group. Furthermore there was no difference in FXYD-3 expression and time to diagnosis of local recurrence between patients who received preoperative radiotherapy and those without. Conclusion: Previous findings indicated that FXYD-3 expression may be used as a marker of decreased sensitivity to radiotherapy or even overall survival. We were unable to confirm this in a cohort of rectal cancer patients who developed local recurrence.

Keywords

References

  1. Dahlberg M, Pahlman L, Bergstrom R, Glimelius B. Improved survival in patients with rectal cancer: a population-based register study. Br J Surg 1998;85:515-20. https://doi.org/10.1046/j.1365-2168.1998.00603.x
  2. Glimelius B, Gronberg H, Jarhult J, Wallgren A, Cavallin-Stahl E. A systematic overview of radiation therapy effects in rectal cancer. Acta Oncol 2003;42:476-92. https://doi.org/10.1080/02841860310012301
  3. Kapiteijn E, Marijnen CA, Nagtegaal ID, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 2001;345:638-46. https://doi.org/10.1056/NEJMoa010580
  4. Birgisson H, Pahlman L, Gunnarsson U, Glimelius B; Swedish Rectal Cancer Trial Group. Adverse effects of preoperative radiation therapy for rectal cancer: long-term follow-up of the Swedish Rectal Cancer Trial. J Clin Oncol 2005;23:8697-705. https://doi.org/10.1200/JCO.2005.02.9017
  5. Birgisson H, Pahlman L, Gunnarsson U, Glimelius B. Occurrence of second cancers in patients treated with radiotherapy for rectal cancer. J Clin Oncol 2005;23:6126-31. https://doi.org/10.1200/JCO.2005.02.543
  6. Birgisson H, Pahlman L, Gunnarsson U, Glimelius B. Late adverse effects of radiation therapy for rectal cancer: a systematic overview. Acta Oncol 2007;46:504-16. https://doi.org/10.1080/02841860701348670
  7. Pettersson D, Cedermark B, Holm T, et al. Interim analysis of the Stockholm III trial of preoperative radiotherapy regimens for rectal cancer. Br J Surg 2010;97:580-7. https://doi.org/10.1002/bjs.6914
  8. Pettersson D, Holm T, Iversen H, Blomqvist L, Glimelius B, Martling A. Preoperative short-course radiotherapy with delayed surgery in primary rectal cancer. Br J Surg 2012;99:577-83. https://doi.org/10.1002/bjs.7796
  9. Glimelius B, Isacsson U, Jung B, Pahlman L. Radiotherapy in addition to radical surgery in rectal cancer: evidence for a dose-response effect favoring preoperative treatment. Int J Radiat Oncol Biol Phys 1997;37:281-7. https://doi.org/10.1016/S0360-3016(96)00510-X
  10. Kuremsky JG, Tepper JE, McLeod HL. Biomarkers for response to neoadjuvant chemoradiation for rectal cancer. Int J Radiat Oncol Biol Phys 2009;74:673-88. https://doi.org/10.1016/j.ijrobp.2009.03.003
  11. Adell G, Sun XF, Stal O, Klintenberg C, Sjodahl R, Nordenskjold B. p53 status: an indicator for the effect of preoperative radiotherapy of rectal cancer. Radiother Oncol 1999;51:169-74. https://doi.org/10.1016/S0167-8140(99)00041-9
  12. Knutsen A, Adell G, Sun XF. Survivin expression is an independent prognostic factor in rectal cancer patients with and without preoperative radiotherapy. Int J Radiat Oncol Biol Phys 2004;60:149-55. https://doi.org/10.1016/j.ijrobp.2004.02.007
  13. Wallin AR, Svanvik J, Adell G, Sun XF. Expression of PRL proteins at invasive margin of rectal cancers in relation to preoperative radiotherapy. Int J Radiat Oncol Biol Phys 2006;65:452-8. https://doi.org/10.1016/j.ijrobp.2005.12.043
  14. Pfeifer D, Gao J, Adell G, Sun XF. Expression of the p73 protein in rectal cancers with or without preoperative radiotherapy. Int J Radiat Oncol Biol Phys 2006;65:1143-8. https://doi.org/10.1016/j.ijrobp.2006.02.028
  15. Loftas P, Onnesjo S, Widegren E, et al. Expression of FXYD-3 is an independent prognostic factor in rectal cancer patients with preoperative radiotherapy. Int J Radiat Oncol Biol Phys 2009;75:137-42. https://doi.org/10.1016/j.ijrobp.2008.10.076
  16. Bibert S, Roy S, Schaer D, Felley-Bosco E, Geering K. Structural and functional properties of two human FXYD3 (Mat-8) isoforms. J Biol Chem 2006;281:39142-51. https://doi.org/10.1074/jbc.M605221200
  17. Grzmil M, Voigt S, Thelen P, Hemmerlein B, Helmke K, Burfeind P. Up-regulated expression of the MAT-8 gene in prostate cancer and its siRNA-mediated inhibition of expression induces a decrease in proliferation of human prostate carcinoma cells. Int J Oncol 2004;24:97-105.
  18. Kayed H, Kleeff J, Kolb A, et al. FXYD3 is overexpressed in pancreatic ductal adenocarcinoma and influences pancreatic cancer cell growth. Int J Cancer 2006;118:43-54. https://doi.org/10.1002/ijc.21257
  19. Syk E, Lenander C, Nilsson PJ, Rubio CA, Glimelius B. Tumour budding correlates with local recurrence of rectal cancer. Colorectal Dis 2011;13:255-62. https://doi.org/10.1111/j.1463-1318.2009.02119.x
  20. Syk E, Glimelius B, Nilsson PJ. Factors influencing local failure in rectal cancer: analysis of 2315 patients from a populationbased series. Dis Colon Rectum 2010;53:744-52. https://doi.org/10.1007/DCR.0b013e3181cf8841
  21. Ragnhammar P, Brorsson B, Nygren P, Glimelius B. A prospective study of the use of chemotherapy in Sweden and assessment of the use in relation to scientific evidence. Acta Oncol 2001;40:391-411. https://doi.org/10.1080/02841860117663
  22. Meding S, Balluff B, Elsner M, et al. Tissue-based proteomics reveals FXYD3, S100A11 and GSTM3 as novel markers for regional lymph node metastasis in colon cancer. J Pathol 2012;228:459-70. https://doi.org/10.1002/path.4021

Cited by

  1. Prognostic significance of survivin in rectal cancer patients treated with surgery and postoperative concurrent chemo-radiation therapy vol.7, pp.38, 2016, https://doi.org/10.18632/oncotarget.10445
  2. Seven low-mass ions in pretreatment serum as potential predictive markers of the chemoradiotherapy response of rectal cancer vol.27, pp.8, 2016, https://doi.org/10.1097/cad.0000000000000391